New First-Line Treatment Approved for NSCLC with an EGFR Mutation

2018-09-28T14:51:23-05:00September 28th, 2018|Hot Topics, News|

Friday, September 28, 2018 – Today the Food and Drug Administration approved VIZIMPRO tablets (dacomitinib) for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with an EGFR (epidermal growth factor receptor) mutation. Approval was based on a randomized trial that showed a significant improvement in progression-free survival for patients who received VIZIMPRO compared to the standard-of-care treatment. VIZIMPRO, an EGFR inhibitor targeted therapy, is an oral drug that is taken once a day. The following treatments [...]

FDA Approves Tagrisso as First-line Treatment for NSCLC

2018-04-23T13:55:25-05:00April 19th, 2018|Hot Topics, News|

Thursday, April 19, 2018 – This week the Food and Drug Administration (FDA) approved targeted therapy drug, osimertinib (Tagrisso), as a frontline treatment for patients with non-small cell lung cancer (NSCLC) who have tumors with the EGFR mutations. The approval is based off results from a study showing that Tagrisso as a first-line treatment prevented the cancer from progressing for 8.7 months longer than erlotinib (Tarceva) and gefitinib (Iressa). Up until this point, Tagrisso was approved as a second-line treatment [...]

A Breath Test Leading to Global Access to Care

2018-03-21T19:23:19-05:00February 1st, 2018|Hot Topics, News|

By Dr. Robert Smyth, MB, MSc As a trainee in pulmonary medicine, lung cancer has long interested me. It is the leading cancer killer worldwide and estimated to be responsible for 1.6 million deaths, about a fifth of all deaths caused by cancer.   The highest estimated rates of lung cancer occur in Europe and North America, but with an estimated 300 million smokers in China, Asia is now also at the forefront of this continuing global battle with 51% of [...]

FDA expands approval of Gilotrif (afatinib) for NSCLC

2019-05-20T16:57:20-05:00January 17th, 2018|Hot Topics, News|

Tuesday, January 16, 2018 – The FDA expanded approval of Gilotrif (afatinib), a first-line treatment for patients with non-small cell lung carcinoma (NSCLC) that is epidermal growth factor receptor (EGFR) mutation-positive. Patients with lung cancers with EGFR S768I, L861Q and G719X may now take Gilotrif. Gilotrif, an oral, once-daily EGFR-directed therapy developed by Boehringer Ingelheim, is currently approved in the U.S. to treat people with NSCLC that has certain EGFR gene changes, has spread to other parts of the body [...]